Rituximab-related viral infections in lymphoma patients

References

• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58–60
   PubMed Web of Science ®Google Scholar
• Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001; 68: 292–294
   PubMed Web of Science ®Google Scholar
• Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000
   PubMed Web of Science ®Google Scholar
• Padate B P, Keidan J. Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab. Clin Lab Haematol 2006; 28: 69–71
   PubMedGoogle Scholar
• Huang C, Slater B, Rudd R, Parchuri N, Hull R, Dupuis M, et al. First isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis 2002; 8: 1367–1371
   PubMed Web of Science ®Google Scholar
• Goldberg S L, Pecora A L, Alter R S, Kroll M S, Rowley S D, Waintraub S E, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486–1488
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456–473
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention, Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000; 6(6a)659–713, 715; 717 – 727; quiz 729 – 733
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas A D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68–69
   PubMed Web of Science ®Google Scholar
• Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189–191
   PubMedGoogle Scholar
• Law J K, Ho J K, Hoskins P J, Erb S R, Steinbrecher U P, Yoshida E M. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085–1089
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627–629
   PubMed Web of Science ®Google Scholar
• Soong Y L, Lee K M, Lui H F, Chow W C, Tao M, Li Er Loong S. Hepatitis B reactivation in a patient receiving radiolabeled rituximab. Ann Hematol 2005; 84: 61–62
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Ng H J, Lim L C. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549–552
   PubMed Web of Science ®Google Scholar
• Hernandez J A, Diloy R, Salat D, del Rio N, Martinez X, Castellvi J M. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2003; 88: ECR22
   PubMedGoogle Scholar
• Zell J A, Yoon E J, Ignatius Ou S H, Hoefs J C, Chang J C. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005; 16: 83–85
   PubMed Web of Science ®Google Scholar
• Westhoff T H, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer J H, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930
   PubMed Web of Science ®Google Scholar
• Heider U, Fleissner C, Zavrski I, Jakob C, Dietzel T, Eucker J, et al. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection. Eur J Haematol 2004; 72: 64–66
   PubMed Web of Science ®Google Scholar
• Dai M S, Chao T Y, Kao W Y, Shyu R Y, Liu T M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769–774
   PubMed Web of Science ®Google Scholar
• Ozgonenel B, Moonka D, Savasan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 2006; 81: 302
   PubMed Web of Science ®Google Scholar
• Skrabs C, Muller C, Agis H, Mannhalter C, Jager U. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002; 16: 1884–1886
   PubMed Web of Science ®Google Scholar
• Niscola P, Del Principe M I, Maurillo L, Venditti A, Buccisano F, Piccioni D, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 1840–1841
   PubMed Web of Science ®Google Scholar
• Jaeger G, Neumeister P, Brezinschek R, Hofler G, Quehenberger F, Linkesch W, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 2002; 69: 21–26
   PubMed Web of Science ®Google Scholar
• Mimidis K, Tsatalas C, Margaritis D, Martinis G, Spanoudakis E, Kotsiou S, et al. Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol 2002; 107: 49–51
   PubMed Web of Science ®Google Scholar
• Law J K, Ali J A, Harrigan P R, Sherlock C H, Savage K J, Yoshida E M. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 2006; 81: 969–972
   PubMed Web of Science ®Google Scholar
• Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053–1056
   PubMed Web of Science ®Google Scholar
• Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721–724
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580
   PubMed Web of Science ®Google Scholar
• Unluturk U, Aksoy S, Yonem O, Bayraktar Y, Tekuzman G. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin's lymphoma patient. World J Gastroenterol 2006; 12: 1978–1979
   PubMed Web of Science ®Google Scholar
• Nomura K, Kamitsuji Y, Kono E, Matsumoto Y, Yoshida N, Konishi H, et al. Severe cytomegalovirus enterocolitis after standard chemotherapy for non-Hodgkin's lymphoma. Scand J Gastroenterol 2005; 40: 604–606
   PubMed Web of Science ®Google Scholar
• Damaj G, Charbonnier A, Bouabdallah R, Vey N, Coso D, Stoppa A M, et al. Monoclonal antibodies and cytomegalovirus infections. Eur J Haematol 2004; 73: 73–74
   PubMed Web of Science ®Google Scholar
• Vallet S, Tempescul A, Tran A, Legrand-Quillien M C, Narbonne V, Berthou C. Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Ann Hematol 2005; 84: 545–547
   PubMed Web of Science ®Google Scholar
• Byrd J C, Peterson B L, Morrison V A, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14
   PubMed Web of Science ®Google Scholar
• Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 894–895
   PubMed Web of Science ®Google Scholar
• McIlwaine L M, Fitzsimons E J, Soutar R L. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post Rituximab and autologous stem cell transplantation. Clin Lab Haematol 2001; 23: 253–254
   PubMedGoogle Scholar
• Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003; 36: e47–e49
   PubMed Web of Science ®Google Scholar
• Archimbaud C, Bailly J L, Chambon M, Tournilhac O, Travade P, Peigue-Lafeuille H. Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000. J Clin Microbiol 2003; 41: 4605–4610
   PubMed Web of Science ®Google Scholar
• Sharma V R, Fleming D R, Slone S P. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184–1186
   PubMed Web of Science ®Google Scholar
• Isobe Y, Sugimoto K, Shiraki Y, Nishitani M, Koike K, Oshimi K. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004; 77: 370–373
   PubMed Web of Science ®Google Scholar
• Mawhorter S D, Sierk A, Staugaitis S M, Avery R K, Sobecks R, Prayson R A, et al. Fatal West Nile virus infection after rituximab/fludarabine – induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2005; 6: 248–250
   PubMedGoogle Scholar
• Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni A M. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 100: 1104–1105
   PubMed Web of Science ®Google Scholar
• Scheinpflug K, Schalk E, Reschke K, Franke A, Mohren M. Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma. A case report. Exp Clin Endocrinol Diabetes 2006; 114: 31–34
   PubMed Web of Science ®Google Scholar
• Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006; 17: 1051–1059
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S, Bertoni F, Waltzer U, Fey M F, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705–711
   PubMed Web of Science ®Google Scholar
• Cheson B D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–2448
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Cornely O A, Ullmann A J, Heidecke C N, Karthaus M. Opportunistic infections (OI) following monoclonal antibody treatment. J Clin Oncol ASCO Ann Meeting Proc 2005; 23(June 1, Suppl)2562, 16S, Part I of II
   Google Scholar
• Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis. Cancer Invest 2006; 24: 548–552
   PubMed Web of Science ®Google Scholar
• Yeo W, Zee B, Zhong S, Chan P K, Wong W L, Ho W M, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306–1311
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58–62
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan P K, Ho W M, Zee B, Lam K C, Lei K I, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927–934
   PubMed Web of Science ®Google Scholar
• Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann Hematol 2002; 81: 48–49
   PubMed Web of Science ®Google Scholar
• Lim L L, Wai C T, Lee Y M, Kong H L, Lim R, Koay E, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16: 1939–1944
   PubMed Web of Science ®Google Scholar
• Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006; 28: 211–214
   PubMedGoogle Scholar
• Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054–3061
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G, Tucci F A, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101: 3818–3826
   PubMed Web of Science ®Google Scholar